Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Business Wire (Mon, 6-Apr 8:00 AM ET)
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Business Wire (Thu, 26-Mar 8:00 AM ET)
Business Wire (Tue, 24-Feb 8:00 AM ET)
Business Wire (Wed, 18-Feb 9:00 AM ET)
Business Wire (Wed, 11-Feb 7:00 AM ET)
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Business Wire (Mon, 2-Feb 7:00 AM ET)
Independent Analysis Sees Vyome’s VT-1953 Asset Value Approaching $1 Billion After Phase 3 Study
Market Chameleon (Tue, 27-Jan 3:20 AM ET)
Business Wire (Tue, 27-Jan 8:00 AM ET)
Vyome’s AI Acquisition Signals Strategic Shift Toward Digital Inflammation Therapies
Market Chameleon (Mon, 29-Sep 3:38 AM ET)
Vyome's VT-1908 Shows Promise for Uveitis Treatment, Targets $3B Market Opportunity
Market Chameleon (Wed, 17-Sep 5:53 AM ET)
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Vyome Holdings trades on the NASDAQ stock market under the symbol HIND.
As of April 15, 2026, HIND stock price declined to $2.24 with 14,796 million shares trading.
HIND has a beta of 1.46, meaning it tends to be more sensitive to market movements. HIND has a correlation of 0.02 to the broad based SPY ETF.
HIND has a market cap of $15.72 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that HIND belongs to (by Net Assets): VXF.
HIND support price is $2.13 and resistance is $2.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIND shares will trade within this expected range on the day.
